SCHEMBL6160396

SCHEMBL6160396

Cc1cc(Cl)ccc1-n1ncc(C(=O)c2cccc(-c3cccnc3)c2)c1N

nearest known ligand 0.67

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 8/20 0.67
FGFR1 P11362 5/20 0.51
FGFR2 P21802 5/20 0.51
FGFR3 P22607 5/20 0.51
SRC P12931 2/20 0.51
FGFR4 P22455 2/20 0.51
KDR P35968 2/20 0.51
SCN9A Q15858 2/20 0.47
SCN5A Q14524 1/20 0.47
ABL1 P00519 1/20 0.45
BCR P11274 1/20 0.45
BTK Q06187 1/20 0.44
KMO O15229 1/20 0.43
KEAP1 Q14145 1/20 0.43
NFE2L2 Q16236 1/20 0.43
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6160881 0.90 MAPK14 (0.69) MAPK14FGFR1FGFR2FGFR3SRC
Hydrochloric Acid SCHEMBL6157974 0.89 MAPK14 (0.68) MAPK14FGFR1FGFR2FGFR3SRC
SCHEMBL6160656 0.88 MAPK14 (0.69) MAPK14FGFR1FGFR2FGFR3SRC
SCHEMBL27501408 0.87 MAPK14 (0.65) MAPK14FGFR1FGFR2FGFR3SRC
SCHEMBL6159379 0.83 MAPK14 (0.57) MAPK14FGFR1FGFR2FGFR3SRC
SCHEMBL6160359 0.81 MAPK14 (0.68) MAPK14FGFR1FGFR2FGFR3SRC
SCHEMBL6159146 0.81 MAPK14 (0.81) MAPK14FGFR1FGFR2FGFR3KEAP1
SCHEMBL6160879 0.80 MAPK14 (1.00) MAPK14KMO
Hydrochloric Acid SCHEMBL6160861 0.80 MAPK14 (0.98) MAPK14KMO
SCHEMBL6292073 0.80 MAPK14 (0.70) MAPK14FGFR1FGFR2FGFR3SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6979693-B2 Pyrazole derivatives-p38 MAP kinase inhibitors SYNTEX (U.S.A.) LLC (US) 2005-12-27 US disclosed
EP-1075467-B1 PYRAZOLE DERIVATIVES AS P-38 MAP KINASE INHIBITORS HOFFMANN LA ROCHE (CH) 2005-03-30 EP disclosed
US-20030018051-A1 Pyrazole derivatives - p38 MAP kinase inhibitors GOLDSTEIN DAVID MICHAEL (US) 2003-01-23 US disclosed
US-20020156114-A1 Pyrazole derivatives - p38 MAP kinase inhibitors GOLDSTEIN DAVID MICHAEL (US) 2002-10-24 US disclosed
US-6444696-B1 1-ARYL OR HETEROARYL SUBSTITUTED 5-AMINO-4 CARBONYLPYRAZOLE DERIVATIVES; ANTIINFLAMMATORY AGENTS SYNTEX (U.S.A.) LLC 2002-09-03 US disclosed
US-20020103245-A1 Pyrazole derivatives P38 MAP kinase inhibitors GOLDSTEIN DAVID MICHAEL (US) 2002-08-01 US disclosed
US-6376527-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES SYNTEX (U.S.A.) LLC 2002-04-23 US disclosed
US-6316466-B1 Pyrazole derivatives P-38 MAP kinase inhibitors SYNTEX (U.S.A.) LLC 2001-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030018051-A1 Pyrazole derivatives - p38 MAP kinase inhibitors MAPK1, MAPK8, MAP3K8 MAPK14 32/4885FGFR1 1317/4885FGFR2 2815/4885
US-20020103245-A1 Pyrazole derivatives P38 MAP kinase inhibitors MAPK1, MAPK8, MAPKAPK2 MAPK14 34/4885FGFR1 1656/4885FGFR2 3098/4885
US-20020156114-A1 Pyrazole derivatives - p38 MAP kinase inhibitors MAPK1, MAPK8, MAP3K8 MAPK14 32/4885FGFR1 1317/4885FGFR2 2815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.